PT2606125T - Cells expressing th1 characteristics and cytolytic properties - Google Patents

Cells expressing th1 characteristics and cytolytic properties

Info

Publication number
PT2606125T
PT2606125T PT118188846T PT11818884T PT2606125T PT 2606125 T PT2606125 T PT 2606125T PT 118188846 T PT118188846 T PT 118188846T PT 11818884 T PT11818884 T PT 11818884T PT 2606125 T PT2606125 T PT 2606125T
Authority
PT
Portugal
Prior art keywords
cells expressing
cytolytic properties
cytolytic
properties
expressing
Prior art date
Application number
PT118188846T
Other languages
Portuguese (pt)
Inventor
Har-Noy Michael
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of PT2606125T publication Critical patent/PT2606125T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
PT118188846T 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties PT2606125T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US201161495055P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
PT2606125T true PT2606125T (en) 2018-02-27

Family

ID=45594250

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118188846T PT2606125T (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Country Status (18)

Country Link
US (3) US20120045423A1 (en)
EP (1) EP2606125B1 (en)
JP (2) JP6408219B2 (en)
KR (1) KR101900807B1 (en)
CN (2) CN108245673A (en)
AU (1) AU2011291477B2 (en)
BR (1) BR112013003989B1 (en)
CA (1) CA2808873C (en)
DK (1) DK2606125T3 (en)
ES (1) ES2660577T3 (en)
HU (1) HUE036094T2 (en)
IL (1) IL224813B (en)
NO (1) NO2606125T3 (en)
PL (1) PL2606125T3 (en)
PT (1) PT2606125T (en)
SG (2) SG187846A1 (en)
TR (1) TR201802334T4 (en)
WO (1) WO2012024666A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045423A1 (en) * 2010-08-20 2012-02-23 Immunovative Therapies Ltd. Cells expressing TH1 characteristics and cytolytic properties
KR101697473B1 (en) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 Method for Preparation of Natural Killer Cells Using T Cells
BR112017018368B1 (en) 2015-04-22 2022-08-02 Curevac Ag COMPOSITION CONTAINING RNA FOR USE IN THE TREATMENT OR PROPHYLAXIS OF TUMOR AND/OR CANCER DISEASES, AND USE OF AN RNA FOR THE PREPARATION OF THE COMPOSITION
JP7337373B2 (en) * 2019-07-29 2023-09-04 サイアス株式会社 Method for producing antigen-specific T cells
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US7722863B2 (en) 2002-08-23 2010-05-25 Multimmune Gmbh Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20120045423A1 (en) 2010-08-20 2012-02-23 Immunovative Therapies Ltd. Cells expressing TH1 characteristics and cytolytic properties
PT2573166T (en) * 2004-02-26 2016-07-07 Immunovative Therapies Ltd Methods for preparing t-cells for cell therapy

Also Published As

Publication number Publication date
EP2606125B1 (en) 2017-11-22
US20130196428A1 (en) 2013-08-01
EP2606125A4 (en) 2014-03-19
JP2013536232A (en) 2013-09-19
NO2606125T3 (en) 2018-04-21
DK2606125T3 (en) 2018-03-05
SG10201510524TA (en) 2016-01-28
CA2808873A1 (en) 2012-02-23
WO2012024666A2 (en) 2012-02-23
HUE036094T2 (en) 2018-06-28
BR112013003989B1 (en) 2020-11-24
KR20130103485A (en) 2013-09-23
KR101900807B1 (en) 2018-11-08
JP6525946B2 (en) 2019-06-05
JP2017061558A (en) 2017-03-30
AU2011291477A1 (en) 2013-04-04
AU2011291477B2 (en) 2016-07-28
CA2808873C (en) 2020-02-18
PL2606125T3 (en) 2018-05-30
US20120045423A1 (en) 2012-02-23
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
BR112013003989A2 (en) 2017-11-14
CN103068973A (en) 2013-04-24
US20130195825A1 (en) 2013-08-01
ES2660577T3 (en) 2018-03-23
IL224813B (en) 2020-06-30
JP6408219B2 (en) 2018-10-17
CN108245673A (en) 2018-07-06
EP2606125A2 (en) 2013-06-26
TR201802334T4 (en) 2018-03-21
SG187846A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
IL221511A (en) Bisaryl-linked aryltriazolones and their use
HK1184488A1 (en) Human facilitating cells and uses thereof
EP2603117A4 (en) Interlocking cutlery and related methods
GB201012175D0 (en) Procedure and mechanisms
ZA201208173B (en) Peptices and their use
EP2558137A4 (en) Methods and combination
HRP20182083T1 (en) Novel combination and use
EP2608785A4 (en) Lipomacrocycles and uses thereof
PT2563806E (en) Human leukolectins and uses thereof
SG10201510524TA (en) Cells expressing th1 characteristics and cytolytic properties
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
GB201017820D0 (en) Cells and devices
EP2529013A4 (en) Novel -glucosidase and uses thereof
EP2542967A4 (en) High and low value application state
EP2619571A4 (en) Human b1 cells and uses thereof
SG10201703686TA (en) Thioesterases and their use
EP2638160A4 (en) Nuclions and ribocapsids
GB201001384D0 (en) Light-fitting and associated methods
GB201117299D0 (en) Zinc-oxygen cell and its application
GB201020268D0 (en) Composition and uses
ZA201104629B (en) Closure and closure arrangement
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods